What happens when GLP-1 treatment stops

The question most clinics do not answer before you start

It is also the question with the clearest evidence, and knowing it before the first injection changes what you are agreeing to.

What the withdrawal trials showed

Two trials were designed specifically to answer this, by taking people who had lost weight on treatment and stopping it.

• STEP 1 extension. Participants who had completed 68 weeks of treatment were followed for a year after both treatment and lifestyle support ended. On average they regained around two‑thirds of the weight they had lost. Cardiometabolic improvements — blood pressure, lipids, glucose markers — also moved back towards where they started.
• STEP 4. After 20 weeks of treatment, participants either continued or switched to placebo. Those who continued went on losing. Those switched to placebo regained.

The finding is consistent and unsurprising once stated: the effect lasts while the medicine is taken. It is not a course that resets anything.

Why this happens

Nothing about it is mysterious, and it is not a failure on the patient's part.

These medicines work by acting on appetite signalling. Remove the medicine and the signalling returns to where it was. Added to that is the body's ordinary defence of lost weight — reduced energy expenditure and shifted hunger hormones, which persist long after a diet ends.

So on stopping, the person faces their original appetite plus the biological response to having lost weight. Regain under those conditions is the expected outcome, not the exceptional one.

The muscle problem, and why it compounds

Weight lost rapidly includes lean tissue. Weight regained tends to be preferentially fat. Cycle through that more than once and body composition can end up worse than at the start, at the same weight on the scale.

This is the strongest practical argument for protein intake and resistance training during treatment rather than after it, and for not treating the scale as the measure of success.

What this means for how treatment should be framed

If the effect depends on continuation, then this is management of a chronic condition — the same model as blood pressure or thyroid treatment. Nobody expects blood pressure to stay down after the tablets stop.

Several consequences follow, and they are worth asking about before starting rather than after:

1. What is the plan if I stop? Any honest answer includes the likelihood of regain.
2. What is the cost over a year, and over five? Not the cost of the first month.
3. What happens if it becomes unavailable or unaffordable? Supply of these medicines has been interrupted internationally before.
4. What is being done to preserve muscle?
5. What would make you recommend stopping? A clinic with no stopping criteria has not thought past the sale.

What is not known

Several things, and they are the active questions in the field rather than settled points:

• Whether a slower, tapered withdrawal changes the regain pattern. Plausible, not established.
• Whether intermittent or lower‑dose maintenance preserves some benefit at lower cost. Under study.
• What very long‑term continuous use looks like over decades — the medicines have not been used that way for long enough.
• Whether the metabolic improvements leave any lasting benefit after the weight returns. The withdrawal data suggest most of it reverses, but that is a short follow‑up.

Where this leaves a decision

Not where marketing puts it. These medicines produce real, measurable effects in people who need them, and the trials are strong. What the same trials show is that the effect is conditional on continuing.

That is not an argument against treatment. It is an argument for entering it with the right expectation — and for being suspicious of any programme sold with an end date and no account of what happens afterwards.

The boundary

Whether to start, continue or stop is a clinical decision made with a physician who knows your measurements and your circumstances. The only thing this page argues is that the question should be asked at the beginning rather than discovered at the end.